Articles |
the Wallenberg Laboratory for Cardiovascular Research, Sahlgrenska University Hospital, Goteborg University, Sweden (E.H.-C., B.R., P.S.); the UNIGEN Center for Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway (S.A., R.S., B.J.); and the Department of Gynecology, Ostra Hospital, Gothenburg, Sweden (E.S.).
Correspondence to Eva Hurt-Camejo, PhD, Wallenberg Laboratory, Fack 16, Sahlgrenska University Hospital, Gothenburg 41 345, Sweden. E-mail eva.hurt@wlab.wall.gu.se.
Secretory nonpancreatic type II phospholipase A2 (snpPLA2) hydrolyzes fatty acids at the sn-2 position in phospholipids releasing free fatty acids (FFAs) and lysophospholipids. These products may act as intracellular second messengers or can be further metabolized into proinflammatory lipid mediators. The presence of snpPLA2 in extracellular fluids and serum during inflammation has suggested a role of the enzyme in this process. However, the presence of snpPLA2 in a variety of normal tissues suggests that snpPLA2 may also have physiological functions. Atherosclerosis appears to have an inflammatory component. Here we report on the snpPLA2 localization in normal and atherosclerotic lesions and on the properties of the isolated enzyme. A strong snpPLA2 immunoreactivity was observed in the arterial media that was colocalized with
-actinpositive vascular smooth muscle cells (SMCs) in both normal and atherosclerotic vessels. In aortic atherosclerotic lesions, snpPLA2 was observed colocalized with CD68-positive macrophages and HHF-35positive SMCs and extracellularly in the lipid core. snpPLA2 was isolated from human normal arteries and from aorta with lesions. The enzyme was isolated by acid extraction of normal arterial tissues followed by immunoaffinity chromatography. The purified snpPLA2 had an expected molecular weight of 14 kD by polyacrylamide gel electrophoresis and appeared as a single band in immunoblotting. The enzymatic activity was followed by measuring release of fatty acids from phospholipid liposomes or LDL as substrates. The enzymatic activity was inhibited with two specific inhibitors for human snpPLA2: (1) monoclonal antibody 187 and (2) LY311727, a synthetic selective inhibitor. The mRNA for snpPLA2 was detected with reverse transcriptase polymerase chain reaction. These results indicate that snpPLA2 is present in human arteries and that it is able to hydrolyze phospholipids in LDL. The results support the hypothesis that snpPLA2 can release proinflammatory lipids at places of LDL deposition in the arterial wall.
Key Words: atherosclerosis vascular smooth muscle cells inflammation macrophages
This article has been cited by other articles:
![]() |
E. Ibeas, L. Fuentes, R. Martin, M. Hernandez, and M. L. Nieto Secreted phospholipase A2 type IIA as a mediator connecting innate and adaptive immunity: new role in atherosclerosis Cardiovasc Res, September 20, 2008; (2008) cvn234v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ravaux, C. Denoyelle, C. Monne, I. Limon, M. Raymondjean, and K. El Hadri Inhibition of Interleukin-1{beta}-Induced Group IIA Secretory Phospholipase A2 Expression by Peroxisome Proliferator-Activated Receptors (PPARs) in Rat Vascular Smooth Muscle Cells: Cooperation between PPAR{beta} and the Proto-Oncogene BCL-6 Mol. Cell. Biol., December 1, 2007; 27(23): 8374 - 8387. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T.E. Wootton, N. L. Arora, F. Drenos, S. R. Thompson, J. A. Cooper, J. W. Stephens, S. J. Hurel, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, et al. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study Hum. Mol. Genet., June 15, 2007; 16(12): 1437 - 1444. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Mallat, J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N. J. Wareham, R. Luben, K.-T. Khaw, et al. Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study Arterioscler. Thromb. Vasc. Biol., May 1, 2007; 27(5): 1177 - 1183. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Bostrom, B. B. Boyanovsky, C. T. Jordan, M. P. Wadsworth, D. J. Taatjes, F. C. de Beer, and N. R. Webb Group V Secretory Phospholipase A2 Promotes Atherosclerosis: Evidence From Genetically Altered Mice Arterioscler. Thromb. Vasc. Biol., March 1, 2007; 27(3): 600 - 606. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-A. Karabina, I. Brocheriou, G. Le Naour, M. Agrapart, H. Durand, M. Gelb, G. Lambeau, and E. Ninio Atherogenic properties of LDL particles modified by human group X secreted phospholipase A2 on human endothelial cell function FASEB J, December 1, 2006; 20(14): 2547 - 2549. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jaulmes, S. Thierry, B. Janvier, M. Raymondjean, and V. Marechal Activation of sPLA2-IIA and PGE2 production by high mobility group protein B1 in vascular smooth muscle cells sensitized by IL-1{beta} FASEB J, August 1, 2006; 20(10): 1727 - 1729. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Giri, M. Khan, R. Rattan, I. Singh, and A. K. Singh Krabbe disease: psychosine-mediated activation of phospholipase A2 in oligodendrocyte cell death J. Lipid Res., July 1, 2006; 47(7): 1478 - 1492. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rosengren, H. Peilot, M. Umaerus, A.-C. Jonsson-Rylander, L. Mattsson-Hulten, C. Hallberg, P. Cronet, M. Rodriguez-Lee, and E. Hurt-Camejo Secretory Phospholipase A2 Group V: Lesion Distribution, Activation by Arterial Proteoglycans, and Induction in Aorta by a Western Diet Arterioscler. Thromb. Vasc. Biol., July 1, 2006; 26(7): 1579 - 1585. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T.E. Wootton, F. Drenos, J. A. Cooper, S. R. Thompson, J. W. Stephens, E. Hurt-Camejo, O. Wiklund, S. E. Humphries, and P. J. Talmud Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study Hum. Mol. Genet., January 15, 2006; 15(2): 355 - 361. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Mallat, Ph. G. Steg, J. Benessiano, M.-L. Tanguy, K. A. Fox, J.-P. Collet, O. H. Dabbous, P. Henry, K. F. Carruthers, A. Dauphin, et al. Circulating Secretory Phospholipase A2 Activity Predicts Recurrent Events in Patients With Severe Acute Coronary Syndromes J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1249 - 1257. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. J. F. Tietge, D. Pratico, T. Ding, C. D. Funk, R. B. Hildebrand, T. Van Berkel, and M. Van Eck Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress J. Lipid Res., August 1, 2005; 46(8): 1604 - 1614. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Oorni, P. Posio, M. Ala-Korpela, M. Jauhiainen, and P. T. Kovanen Sphingomyelinase Induces Aggregation and Fusion of Small Very Low-Density Lipoprotein and Intermediate-Density Lipoprotein Particles and Increases Their Retention to Human Arterial Proteoglycans Arterioscler. Thromb. Vasc. Biol., August 1, 2005; 25(8): 1678 - 1683. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jaulmes, B. Janvier, M. Andreani, and M. Raymondjean Autocrine and Paracrine Transcriptional Regulation of Type IIA Secretory Phospholipase A2 Gene in Vascular Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., June 1, 2005; 25(6): 1161 - 1167. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Boekholdt, T. T. Keller, N. J. Wareham, R. Luben, S. A. Bingham, N. E. Day, M. S. Sandhu, J. W. Jukema, J. J.P. Kastelein, C. E. Hack, et al. Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study Arterioscler. Thromb. Vasc. Biol., April 1, 2005; 25(4): 839 - 846. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chait, C. Y. Han, J. F. Oram, and J. W. Heinecke Thematic review series: The Immune System and Atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J. Lipid Res., March 1, 2005; 46(3): 389 - 403. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. I. Ghesquiere, M. J. J. Gijbels, M. Anthonsen, P. J. J. van Gorp, I. van der Made, B. Johansen, M. H. Hofker, and M. P. J. de Winther Macrophage-specific overexpression of group IIa sPLA2 increases atherosclerosis and enhances collagen deposition J. Lipid Res., February 1, 2005; 46(2): 201 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Asatryan, R. T. Hamilton, J. M. Isas, J. Hwang, R. Kayed, and A. Sevanian LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein J. Lipid Res., January 1, 2005; 46(1): 115 - 122. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Cederholm, E. Svenungsson, K. Jensen-Urstad, C. Trollmo, A.-K. Ulfgren, J. Swedenborg, G.-Z. Fei, and J. Frostegard Decreased Binding of Annexin V to Endothelial Cells: A Potential Mechanism in Atherothrombosis of Patients With Systemic Lupus Erythematosus Arterioscler. Thromb. Vasc. Biol., January 1, 2005; 25(1): 198 - 203. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Oestvang, D. Bonnefont-Rousselot, E. Ninio, J. K. Hakala, B. Johansen, and M. W. Anthonsen Modification of LDL with human secretory phospholipase A2 or sphingomyelinase promotes its arachidonic acid-releasing propensity J. Lipid Res., May 1, 2004; 45(5): 831 - 838. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Wooton-Kee, B. B. Boyanovsky, M. S. Nasser, W. J.S. de Villiers, and N. R. Webb Group V sPLA2 Hydrolysis of Low-Density Lipoprotein Results in Spontaneous Particle Aggregation and Promotes Macrophage Foam Cell Formation Arterioscler. Thromb. Vasc. Biol., April 1, 2004; 24(4): 762 - 767. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Liu, Y.-H. Li, W.-C. Tsai, T.-H. Chao, L.-M. Tsai, H.-L. Wu, and J.-H. Chen Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention Eur. Heart J., October 2, 2003; 24(20): 1824 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. OSTERUD and E. BJORKLID Role of Monocytes in Atherogenesis Physiol Rev, October 1, 2003; 83(4): 1069 - 1112. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Bousserouel, A. Brouillet, G. Bereziat, M. Raymondjean, and M. Andreani Different effects of n-6 and n-3 polyunsaturated fatty acids on the activation of rat smooth muscle cells by interleukin-1{beta} J. Lipid Res., March 1, 2003; 44(3): 601 - 611. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R. Webb, M. A. Bostrom, S. J. Szilvassy, D. R. van der Westhuyzen, A. Daugherty, and F. C. de Beer Macrophage-Expressed Group IIA Secretory Phospholipase A2 Increases Atherosclerotic Lesion Formation in LDL Receptor-Deficient Mice Arterioscler. Thromb. Vasc. Biol., February 1, 2003; 23(2): 263 - 268. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Y. Hui and P. N. Howles Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis J. Lipid Res., December 1, 2002; 43(12): 2017 - 2030. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Fuentes, M. Hernandez, F. J. Fernandez-Aviles, M. S. Crespo, and M. L. Nieto Cooperation Between Secretory Phospholipase A2 and TNF-Receptor Superfamily Signaling: Implications for the Inflammatory Response in Atherogenesis Circ. Res., October 18, 2002; 91(8): 681 - 688. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Alaoui-El-Azher, Y. Wu, N. Havet, A. Israel, A. Lilienbaum, and L. Touqui Arachidonic Acid Differentially Affects Basal and Lipopolysaccharide-Induced sPLA2-IIA Expression in Alveolar Macrophages through NF-kappa B and PPAR-gamma -Dependent Pathways Mol. Pharmacol., April 1, 2002; 61(4): 786 - 794. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hurt-Camejo, G. Camejo, H. Peilot, K. Oorni, and P. Kovanen Phospholipase A2 in Vascular Disease Circ. Res., August 17, 2001; 89(4): 298 - 304. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Guyton Phospholipid Hydrolytic Enzymes in a 'Cesspool' of Arterial Intimal Lipoproteins : A Mechanism for Atherogenic Lipid Accumulation Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 884 - 886. [Full Text] [PDF] |
||||
![]() |
J. K. Hakala, K. Oorni, M. O. Pentikainen, E. Hurt-Camejo, and P. T. Kovanen Lipolysis of LDL by Human Secretory Phospholipase A2 Induces Particle Fusion and Enhances the Retention of LDL to Human Aortic Proteoglycans Arterioscler. Thromb. Vasc. Biol., June 1, 2001; 21(6): 1053 - 1058. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Hulthe, O. Wiklund, E. Hurt-Camejo, and G. Bondjers Antibodies to Oxidized LDL in Relation to Carotid Atherosclerosis, Cell Adhesion Molecules, and Phospholipase A2 Arterioscler. Thromb. Vasc. Biol., February 1, 2001; 21(2): 269 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Öörni, M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions J. Lipid Res., November 1, 2000; 41(11): 1703 - 1714. [Abstract] [Full Text] |
||||
![]() |
K. Kugiyama, Y. Ota, H. Kawano, H. Soejima, H. Ogawa, S. Sugiyama, H. Doi, and H. Yasue Increase in plasma levels of secretory type II phospholipase A2 in patients with coronary spastic angina Cardiovasc Res, July 1, 2000; 47(1): 159 - 165. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Anthonsen, D. Stengel, D. Hourton, E. Ninio, and B. Johansen Mildly Oxidized LDL Induces Expression of Group IIa Secretory Phospholipase A2 in Human Monocyte-Derived Macrophages Arterioscler. Thromb. Vasc. Biol., May 1, 2000; 20(5): 1276 - 1282. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. J. F. Tietge, C. Maugeais, W. Cain, D. Grass, J. M. Glick, F. C. de Beer, and D. J. Rader Overexpression of Secretory Phospholipase A2 Causes Rapid Catabolism and Altered Tissue Uptake of High Density Lipoprotein Cholesteryl Ester and Apolipoprotein A-I J. Biol. Chem., March 31, 2000; 275(14): 10077 - 10084. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Kovanen and M. O. Pentikainen Secretory Group II Phospholipase A2 : A Newly Recognized Acute-Phase Reactant With a Role in Atherogenesis Circ. Res., March 31, 2000; 86(6): 610 - 612. [Full Text] [PDF] |
||||
![]() |
P. Sartipy, B. Johansen, K. Gasvik, and E. Hurt-Camejo Molecular Basis for the Association of Group IIA Phospholipase A2 and Decorin in Human Atherosclerotic Lesions Circ. Res., March 31, 2000; 86(6): 707 - 714. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Menschikowski, A. Rosner-Schiering, R. Eckey, E. Mueller, R. Koch, and W. Jaross Expression of Secretory Group IIA Phospholipase A2 in Relation to the Presence of Microbial Agents, Macrophage Infiltrates, and Transcripts of Proinflammatory Cytokines in Human Aortic Tissues Arterioscler. Thromb. Vasc. Biol., March 1, 2000; 20(3): 751 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hakkinen, J. S. Luoma, M. O. Hiltunen, C. H. Macphee, K. J. Milliner, L. Patel, S. Q. Rice, D. G. Tew, K. Karkola, and S. Yla-Herttuala Lipoprotein-Associated Phospholipase A2, Platelet-Activating Factor Acetylhydrolase, Is Expressed by Macrophages in Human and Rabbit Atherosclerotic Lesions Arterioscler. Thromb. Vasc. Biol., December 1, 1999; 19(12): 2909 - 2917. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kugiyama, Y. Ota, K. Takazoe, Y. Moriyama, H. Kawano, Y. Miyao, T. Sakamoto, H. Soejima, H. Ogawa, H. Doi, et al. Circulating Levels of Secretory Type II Phospholipase A2 Predict Coronary Events in Patients with Coronary Artery Disease Circulation, September 21, 1999; 100(12): 1280 - 1284. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sartipy, G. Camejo, L. Svensson, and E. Hurt-Camejo Phospholipase A2 Modification of Low Density Lipoproteins Forms Small High Density Particles with Increased Affinity for Proteoglycans and Glycosaminoglycans J. Biol. Chem., September 3, 1999; 274(36): 25913 - 25920. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Hurt-Camejo, B. Rosengren, P. Sartipy, K. Elfsberg, G. Camejo, and L. Svensson CD44, a Cell Surface Chondroitin Sulfate Proteoglycan, Mediates Binding of Interferon-gamma and Some of Its Biological Effects on Human Vascular Smooth Muscle Cells J. Biol. Chem., July 2, 1999; 274(27): 18957 - 18964. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Hakala, K. Oorni, M. Ala-Korpela, and P. T. Kovanen Lipolytic Modification of LDL by Phospholipase A2 Induces Particle Aggregation in the Absence and Fusion in the Presence of Heparin Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1276 - 1283. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ivandic, L. W. Castellani, X.-P. Wang, J.-H. Qiao, M. Mehrabian, M. Navab, A. M. Fogelman, D. S. Grass, M. E. Swanson, M. C. de Beer, et al. Role of Group II Secretory Phospholipase A2 in Atherosclerosis : 1. Increased Atherogenesis and Altered Lipoproteins in Transgenic Mice Expressing Group IIa Phospholipase A2 Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1284 - 1290. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Leitinger, A. D. Watson, S. Y. Hama, B. Ivandic, J.-H. Qiao, J. Huber, K. F. Faull, D. S. Grass, M. Navab, A. M. Fogelman, et al. Role of Group II Secretory Phospholipase A2 in Atherosclerosis : 2. Potential Involvement of Biologically Active Oxidized Phospholipids Arterioscler. Thromb. Vasc. Biol., May 1, 1999; 19(5): 1291 - 1298. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Beasley COX-2 and cytosolic PLA2 mediate IL-1beta -induced cAMP production in human vascular smooth muscle cells Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1369 - H1378. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Sartipy, G. Bondjers, and E. Hurt-Camejo Phospholipase A2 Type II Binds to Extracellular Matrix Biglycan : Modulation of Its Activity on LDL by Colocalization in Glycosaminoglycan Matrixes Arterioscler. Thromb. Vasc. Biol., December 1, 1998; 18(12): 1934 - 1941. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Pruzanski, E. Stefanski, F. C. de Beer, M. C. de Beer, P. Vadas, A. Ravandi, and A. Kuksis Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL J. Lipid Res., November 1, 1998; 39(11): 2150 - 2160. [Abstract] [Full Text] |
||||
![]() |
L. Thommesen, W. Sjursen, K. Gasvik, W. Hanssen, O.-L. Brekke, L. Skattebol, A. K. Holmeide, T. Espevik, B. Johansen, and A. Lagreid Selective Inhibitors of Cytosolic or Secretory Phospholipase A2 Block TNF-Induced Activation of Transcription Factor Nuclear Factor-{kappa}B and Expression of ICAM-1 J. Immunol., October 1, 1998; 161(7): 3421 - 3430. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Romano, E. Romano, S. Bjorkerud, and E. Hurt-Camejo Ultrastructural Localization of Secretory Type II Phospholipase A2 in Atherosclerotic and Nonatherosclerotic Regions of Human Arteries Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 519 - 525. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. L. Schissel, X.-c. Jiang, J. Tweedie-Hardman, T.-s. Jeong, E. H. Camejo, J. Najib, J. H. Rapp, K. J. Williams, and I. Tabas Secretory Sphingomyelinase, a Product of the Acid Sphingomyelinase Gene, Can Hydrolyze Atherogenic Lipoproteins at Neutral pH. IMPLICATIONS FOR ATHEROSCLEROTIC LESION DEVELOPMENT J. Biol. Chem., January 30, 1998; 273(5): 2738 - 2746. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Upston, P. K. Witting, R. Alleva, and R. Stocker Oxidation of Free Fatty Acids in Low Density Lipoprotein by 15-Lipoxygenase Stimulates Nonenzymic, alpha -Tocopherol-mediated Peroxidation of Cholesteryl Esters J. Biol. Chem., November 28, 1997; 272(48): 30067 - 30074. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Peilot, B. Rosengren, G. Bondjers, and E. Hurt-Camejo Interferon-gamma Induces Secretory Group IIA Phospholipase A2 in Human Arterial Smooth Muscle Cells. INVOLVEMENT OF CELL DIFFERENTIATION, STAT-3 ACTIVATION, AND MODULATION BY OTHER CYTOKINES J. Biol. Chem., July 21, 2000; 275(30): 22895 - 22904. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hernandez, L. Fuentes, F. J. Fernandez Aviles, M. S. Crespo, and M. L. Nieto Secretory Phospholipase A2 Elicits Proinflammatory Changes and Upregulates the Surface Expression of Fas Ligand in Monocytic Cells: Potential Relevance for Atherogenesis Circ. Res., January 11, 2002; 90(1): 38 - 45. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |